[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100443617":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":10,"centralContacts":10,"locations":32,"responsibleParty":50,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":10,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Nice","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"MS",null,"Patients with a definite MS diagnosis according to the 2017 McDonald criteria",[13],"Biological: Data analysis",{"label":15,"type":10,"description":16,"interventionNames":17},"Red-flag MS","Patients presenting with clinical, radiological or biological red flags for MS diagnosis who will be ultimately diagnosed as having MS",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Other CNS autoimmune diseases","Patients with a definite diagnostic of CNS autoimmune disease that is not MS",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Controls","Patients with a definite diagnostic of non-inflammatory CNS disorder",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"BIOLOGICAL","Data analysis","Analysis of the data from routine care at the end of the diagnostic work-up",[23,9,19,15],[33],{"facility":5,"status":34,"city":35,"state":10,"zip":10,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Nice","France","FR",{"type":39,"coordinates":40},"Point",[41,42],7.26608,43.70313,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":48,"phoneExt":10,"email":49},"Michael Levraut, MD","CONTACT","+33492034126","levraut.m@chu-nice.fr",{"type":51,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100443617","combined-analysis-of-inflammatory-biomarkers-for-cns-autoimmune-diseases-diagnostic-100443617",false,"NCT05056740","Combined Analysis of Inflammatory Biomarkers for CNS Autoimmune Diseases Diagnostic","Evaluation of a Combined Analysis of Serum and Cerebrospinal Fluid Inflammatory Biomarkers to Help in Etiological Diagnosis of Central Nervous System Autoimmune Diseases","CyBIRD","Inclusion Criteria:\n\n* Patients referred to our center for the diagnostic work-up of White Matter Lesions\n* Patients that need a routine blood analysis\n* Patients that need a routine CSF analysis\n* Non opposition to research consent\n\nExclusion Criteria:\n\n* Patients with a contraindication to perform spinal tap (increase bleeding risk medicine or disease)\n* Patients with a contraindication to MRI (metal prosthesis…)","ALL",{"count":62,"type":63},300,"ESTIMATED","OBSERVATIONAL","Project rationale:\n\nSince 2017, multiple sclerosis diagnosis should match the new McDonald criteria in which a \"no better explanation than MS\" should be fulfilled. However, many patients present with red flags that lead to a complex diagnostic work-up. There are no available biomarkers that permit to confirm or roll out MS diagnosis in such cases. Therefore, we lack biological markers that can help in the diagnosis of patients presenting with suspected MS.\n\nMany studies have found that serum and cerebrospinal fluid (CSF) cytokines could help to differentiate MS from other diseases such as neuromyelitis optica spectrum disorders (i.e., IL-6) or neurosarcoidosis (i.e., sIL-2R). Serum and CSF kappa free light chains have also shown good diagnosis performance in MS. In daily practice, our MS tertiary center already perform the analysis of CSF concentrations of IL-1β, sIL-2R, IL-6, IL-10, and serum and CSF kappa and lambda free light chains to roll out other central nervous system (CNS) autoimmune diseases in patients presenting with white matter hyperintensities (WMH).\n\nObjective:\n\nTo correlate CSF IL-1β, sIL-2R, IL-6, IL-10, serum and CSF kappa and lambda free light chains with the final diagnosis in patients presenting to our MS tertiary center with suspected MS to identify a specific inflammatory biomarker profil involved in MS and other CNS autoimmune diseases.\n\nThe methodology:\n\nThis is an observational study. All patients ongoing a routine diagnostic work-up for suspected MS from june 2020 to june 2022 in our MS tertiary center will be analyzed. Cerebrospinal fluid IL-1β, sIL-2R, IL-6, IL-10, serum and CSF kappa and lambda free light chains will be correlated with the final diagnosis to ultimately find MS associated biomarkers.",[67],"Central Nervous System Diseases","2026-06-25",{"date":70,"type":71},"2026-06-26","ACTUAL",{"date":73,"type":71},"2020-06-01",{"date":75,"type":63},"2027-06-25",{"name":5,"class":6},1]